Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04342936 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 3 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma(H10) | unknown | Phase 3 | 1,952 | European Organisation for Research and Treatment of Cancer - EORTC |
| 1 |
| Feb 3, 2021 |
| clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04539119 | Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA | unknown | Phase 3 | 120 | Ruijin HospitalOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04446130 | Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients | unknown | Phase 3 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04228393 | The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China | unknown | Phase 2 / Phase 3 | 82 | Wei ZhaoOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02186574 | Tenofovir to Prevent HBV Reactivation | unknown | Phase 3 | 184 | University Health Network, TorontoOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT03952572 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 3 | 244 | Peking UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT02767674 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | Phase 3 | 258 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03792620 | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation(MAXDARA) | unknown | Phase 3 | 20 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT03454945 | Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides | unknown | Phase 3 | 30 | Cairo UniversityOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT03623087 | SIMPLE Chemotherapy for NK Lymphoma/Leukaemia | unknown | Phase 3 | 68 | The University of Hong KongOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | unknown | Phase 2 / Phase 3 | 70 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unknown | Phase 3 | 100 | Southwest Hospital, ChinaOTHER | 0 | Jun 12, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT02451774 | Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction(PTX-II) | unknown | Phase 2 / Phase 3 | 44 | Ramón Óscar González-Ramella, Ph.DOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT03479918 | R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) | unknown | Phase 3 | 80 | Elena N.ParovichnikovaNETWORK | 1 | Mar 27, 2018 | clinicaltrials |
| NCT02354313 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients(MCL0208) | unknown | Phase 3 | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Feb 9, 2018 | clinicaltrials |
| NCT03391726 | CART-19 Cells for R/R B-cell Lymphoma(CCFRRBL) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | unknown | Phase 3 | 870 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 5 | Dec 19, 2017 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03229616 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02248428 | Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma(CTd) | unknown | Phase 3 | 130 | Jinling Hospital, ChinaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT03016000 | Thalidomide Maintenance Treatment in DLBCL | unknown | Phase 3 | 226 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03018626 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | unknown | Phase 3 | 402 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02871869 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 2 / Phase 3 | 316 | Xinjiang Medical UniversityOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT03151044 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | unknown | Phase 3 | 408 | FENG Ji-fengOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT03123718 | High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL | unknown | Phase 3 | 205 | Chonnam National University HospitalOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL(MCLelderly) | unknown | Phase 3 | 570 | European Mantle Cell Lymphoma NetworkOTHER | 7 | Mar 7, 2017 | clinicaltrials |
| NCT01449344 | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL((R-HAD)) | unknown | Phase 3 | 128 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 2 | Mar 7, 2017 | clinicaltrials |
| NCT03027739 | CART-19 Cells For MRD Positive CD19+ ALL(CCFMPCA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03023358 | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | unknown | Phase 3 | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT02916420 | Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 73 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02842931 | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | unknown | Phase 3 | 300 | National Research Center for Hematology, RussiaNETWORK | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02777736 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma(CLSG-CNS-001) | unknown | Phase 3 | 500 | Czech Lymphoma Study GroupOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01933711 | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | unknown | Phase 3 | 328 | University Hospital HeidelbergOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02362165 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | unknown | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02722733 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | unknown | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Mar 30, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 8, 2021source: clinicaltrials